男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat

Going above and beyond

What will be Sanofi's R&D goals in the coming years? Reed already has concrete plans in mind - the company will expect 8 major submissions in 2022 and 20 more in the next 3 to 5 years in the fields of immunology, oncology, rare blood disorders and vaccines.

"While I take pride in all our accomplishments as an organization, the progress we have made in immunology & inflammation (I&I) is particularly gratifying for me. Our I&I portfolio four years ago was behind the curve compared to our peers. Today, it is arguably one of the most vibrant elements of Sanofi's pipeline with 15 products in development and our flagship medicine growing rapidly in numbers of patients treated. Moreover, our focus on immunoscience at Sanofi has benefited not only the I&I therapeutic area, but it has also served as the foundation for driving progress across our other therapeutic areas, including neurology, hematology, oncology and vaccines."

" Reviewing our success to-date, it's clear that Sanofi is committed to delivering best-in-class innovation, playing to our strengths, and making the necessary deliberate choices about resource allocation to focus our investments on what matters most for patients. Every day, we have the duty to turn great science into new opportunities for patients, and we will continue to do so in 2022."

Diseases are very close to us, and Sanofi is telling us that medical miracles are also very close to us with each of its attempts for scientific breakthroughs.

For pharmaceutical companies, being R&D-driven and placing clinical value first is not just business logic, but a kind of reverence for life, and also the true meaning behind Sanofi's motto of "Chasing the miracles of science to improve people's life".

As Reed said, "News headlines can make scientific advances appear like overnight successes rather than the evolution of hundreds of small discoveries made throughout decades." Sanofi is fully committed to devoting time, resources, and commitment that will be needed in the pursuit of its mission for patients.

|<< Previous 1 2 3   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 左权县| 郴州市| 南京市| 邻水| 平南县| 沽源县| 鱼台县| 大荔县| 临朐县| 万山特区| 台北市| 即墨市| 曲周县| 千阳县| 特克斯县| 邮箱| 平谷区| 酒泉市| 文昌市| 滕州市| 时尚| 张家川| 龙州县| 涡阳县| 宜兰县| 许昌县| 阳高县| 泸西县| 东山县| 方正县| 赤水市| 滁州市| 香格里拉县| 宜兴市| 腾冲县| 大竹县| 霍城县| 汪清县| 高淳县| 克东县| 巴彦县|